Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice
Eiki Takimoto, … , Michael E. Mendelsohn, David A. Kass
Eiki Takimoto, … , Michael E. Mendelsohn, David A. Kass
Published January 5, 2009
Citation Information: J Clin Invest. 2009;119(2):408-420. https://doi.org/10.1172/JCI35620.
View: Text | PDF
Research Article Cardiology

Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice

  • Text
  • PDF
Abstract

The heart initially compensates for hypertension-mediated pressure overload by enhancing its contractile force and developing hypertrophy without dilation. Gq protein–coupled receptor pathways become activated and can depress function, leading to cardiac failure. Initial adaptation mechanisms to reduce cardiac damage during such stimulation remain largely unknown. Here we have shown that this initial adaptation requires regulator of G protein signaling 2 (RGS2). Mice lacking RGS2 had a normal basal cardiac phenotype, yet responded rapidly to pressure overload, with increased myocardial Gq signaling, marked cardiac hypertrophy and failure, and early mortality. Swimming exercise, which is not accompanied by Gq activation, induced a normal cardiac response, while Rgs2 deletion in Gαq-overexpressing hearts exacerbated hypertrophy and dilation. In vascular smooth muscle, RGS2 is activated by cGMP-dependent protein kinase (PKG), suppressing Gq-stimulated vascular contraction. In normal mice, but not Rgs2–/– mice, PKG activation by the chronic inhibition of cGMP-selective phosphodiesterase 5 (PDE5) suppressed maladaptive cardiac hypertrophy, inhibiting Gq-coupled stimuli. Importantly, PKG was similarly activated by PDE5 inhibition in myocardium from both genotypes, but PKG plasma membrane translocation was more transient in Rgs2–/– myocytes than in controls and was unaffected by PDE5 inhibition. Thus, RGS2 is required for early myocardial compensation to pressure overload and mediates the initial antihypertrophic and cardioprotective effects of PDE5 inhibitors.

Authors

Eiki Takimoto, Norimichi Koitabashi, Steven Hsu, Elizabeth A. Ketner, Manling Zhang, Takahiro Nagayama, Djahida Bedja, Kathleen L. Gabrielson, Robert Blanton, David P. Siderovski, Michael E. Mendelsohn, David A. Kass

×

Figure 7

Regulation of RGS2 by PKG-1α.

Options: View larger image (or click on image) Download as PowerPoint
Regulation of RGS2 by PKG-1α.
(A) PKG is similarly activated with and wi...
(A) PKG is similarly activated with and without concomitant sildenafil treatment in both genotypes. *P < 0.05 versus respective sham; #P < 0.005 versus TAC alone. (B) Subcellular localization of RGS2 and PKG-1α in Rgs2+/+ mouse adult cardiac myocytes by immunohistochemistry using confocal microscope. Images represent baseline (control), ET1 stimulation, ET1 stimulation with PKG inhibitor (ET1+DT2), and PKG stimulation with 8Br-cGMP. More than 20 cells were analyzed from 1 experiment, and experiments were repeated 3 times. Original magnification, ×200. (C) Translocation of PKG-1α to outer membrane with 48 h TAC occurred in both genotypes and declined somewhat after 1 wk in Rgs2+/+ mice but was virtually absent in Rgs2–/– mice at the same time. Sildenafil treatment restored membrane localization and enhanced RGS2 membrane signal in Rgs2+/+ cells, but had no impact in Rgs2–/– cells. Original magnification, ×200. (D) Immunoblot of PKG-1α from cytosolic (soluble [S]) and membrane (particulate [P]) fractions in sham control, 48 h, and 1 wk TAC myocardium. Summary data of particulate/soluble ratio is shown at right (n = 3–6 per group). *P < 0.001 versus sham; †P < 0.001 versus 1 wk TAC; ‡P < 0.001 versus 48 h TAC. Equal protein loading was confirmed by Ponceau staining (Supplemental Figure 4B).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts